Biomarin Pharmaceutical (BMRN) Shares Outstanding (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Shares Outstanding (Entity) data on file, last reported at $193.3 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 0.79% year-over-year to $193.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.3 million (up 0.79% YoY) and the FY2025 annual result came in at $192.3 million, up 0.81% from the prior year.
• Shares Outstanding (Entity) grew to $193.3 million in Q1 2026, from $192.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $193.3 million in Q1 2026 to a low of $184.9 million in Q1 2022.
• A 5-year average of $189.3 million and a median of $189.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) climbed 1.46% — and 2026, when it grew 0.79%.
• Tracing BMRN's Shares Outstanding (Entity) over 5 years: stood at $186.3 million in 2022, then increased by 1.26% to $188.6 million in 2023, then advanced by 1.15% to $190.8 million in 2024, then grew by 0.81% to $192.3 million in 2025, then grew by 0.5% to $193.3 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $193.3 million (Q1 2026), $192.3 million (Q4 2025), and $192.1 million (Q3 2025), per Business Quant data.